EP Patent

EP3378472A1 — Combinations of meglumine

Assigned to DYNAMIS PHARMACEUTICALS Inc · Expires 2018-09-26 · 8y expired

What this patent protects

The invention relates to a method of treating or preventing a condition in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. The invention further relates to a method of improving a physiological function in a sub…

USPTO Abstract

The invention relates to a method of treating or preventing a condition in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. The invention further relates to a method of improving a physiological function in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3378472A1
Jurisdiction
EP
Classification
Expires
2018-09-26
Drug substance claim
No
Drug product claim
No
Assignee
DYNAMIS PHARMACEUTICALS Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.